News Release

HIV drug could stop skin cancer becoming drug-resistant

Peer-Reviewed Publication

Cancer Research UK

An HIV drug could stop one of the early changes in skin cancer cells that leads to them becoming resistant to treatment, according to a Cancer Research UK-funded study published in Cancer Cell today (Monday).

The researchers looked at melanoma skin cancers from 11 patients who had started standard treatment for the cancer**. They found that the cancer cells used a molecular switch to temporarily rewire themselves to become more able to withstand the drugs in the first two weeks of treatment, and then went on to develop permanent resistance through genetic changes.

The HIV drug, called nelfinavir, works by blocking the molecular switch which boosts cells' ability to survive treatment. The research, carried out in mice, suggests that nelfinavir could be used in combination with standard skin cancer treatments to make them more potent and delay drug resistance, making available treatments effective for a longer period of time.

Professor Claudia Wellbrock, lead author from The University of Manchester, said: "In the first few weeks of standard treatment for skin cancer, the cancer cells become stronger and more robust against treatment.

"But if we can target skin cancer cells before they become fully resistant, we would have a much better chance of blocking their escape. And we think this research has brought us one step closer to making this a reality."

Professor Nic Jones, Director of Cancer Research UK's Manchester Cancer Research Centre, said: "Melanoma can be difficult to treat because the cancer becomes resistant to drugs quite quickly. But this exciting research means we might be able to fight back by blocking the first steps towards resistance, so that treatments are effective for longer.

"While drug resistance is a big challenge, we're making great progress. Drug resistance in late stage skin cancer is still a big problem and something we need to tackle. We've seen big steps forward recently with the development of immunotherapies but this exciting approach could stop skin cancer developing resistance at an earlier point."

###

For media enquiries please contact Fiona Dennehy on 020 3469 6770 or, out-of-hours, the duty press officer on 07050-264-059.

Notes to editors:

  • Smith et al., Inhibiting drivers of non-mutational drug-tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell, 2016. DOI: 10.1016/j.ccell.2016.02.003.

**The researchers analysed melanomas from 11 patients undergoing treatment with vemurafenib or a dabrafenib and trametinib combination which are FDA approved. NICE recommends vemurafenib as a possible treatment for metastatic melanoma. Dabrafenib and trametenib combination treatment is under review by NICE and a result is expected in August 2016.

About The University of Manchester

The University of Manchester, a member of the prestigious Russell Group, is the UK's largest single-site university with 38,600 students. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering, multi-disciplinary teaching and research of worldwide significance. The University is one of the country's major research institutions, rated fifth in the UK in terms of 'research power' (REF 2014), and has had no fewer than 25 Nobel laureates either work or study there. The University had an annual income of just over £1 billion in 2014/15. Visit http://www.manchester.ac.uk for further information.

About Cancer Research UK

  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured. For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300-123-1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.